CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 199 enrolled
Drug / intervention
Ruxolitinib Phosphate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00778700
NCT00778700Phase 2Completed
CompareCT.gov

A Double-Blind, Randomized, Vehicle-Controlled Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis

Incyte Corporation·interventional·Posted Oct 23, 2008·Updated Feb 9, 2022

In Brief

A Phase 2 clinical trial evaluating Placebo Cream and Ruxolitinib Phosphate for Psoriasis. Completed, enrolled 199 participants across 28 sites.

Detailed Summary

The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive dressings. There were 4 treatment groups anticipated to have 50 participants in each.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 23, 2008
Enrollment StartOct 28, 2008
Primary CompletionJun 26, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.7 years ago

Interventions

Placebo Creamother

Cream with no active drug

Ruxolitinib Phosphatedrug

Ruxolitinib phosphate cream